IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation

被引:543
作者
Ma, Hak-Ling [1 ]
Liang, Spencer [1 ]
Li, Jing [1 ]
Napierata, Lee [1 ]
Brown, Tom [1 ]
Benoit, Stephen [1 ]
Senices, Mayra [1 ]
Gill, Davinder [1 ]
Dunussi-Joannopoulos, Kyriaki [1 ]
Collins, Mary [1 ]
Nickerson-Nutter, Cheryl [1 ]
Fouser, Lynette A. [1 ]
Young, Deborah A. [1 ]
机构
[1] Wyeth Ayerst Res, Cambridge, MA 02140 USA
关键词
D O I
10.1172/JCI33263
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Psoriasis is a chronic skin disease resulting from the dysregulated interplay between keratinocytes and infiltrating immune cells. We report on a psoriasis-like disease model, which is induced by the transfer of CD4(+)CD45RB(hi)CD25(-) cells to pathogen-free scid/scid mice. Psoriasis-like lesions had elevated levels of antimicrobial peptide and proinflammatory cytokine mRNA. Also, similar to psoriasis, disease progression in this model was dependent on the p40 common to IL-12 and IL-23. To investigate the role of IL-22, a Th17 cytokine, in disease progression, mice were treated with IL-22-neutralizing antibodies. Neutralization of IL-22 prevented the development of disease, reducing acanthosis (thickening of the skin), inflammatory infiltrates, and expression of Th17 cytokines. Direct administration of IL-22 into the skin of normal mice induced both antimicrobial peptide and proinflammatory cytokine gene expression. our data suggest that IL-22, which acts on keratinocytes and other nonhematopoietic cells, is required for development of the autoreactive Th17 cell-dependent disease in this model of skin inflammation. We propose that IL-22 antagonism might be a promising therapy for the treatment of human psoriasis.
引用
收藏
页码:597 / 607
页数:11
相关论文
共 42 条
  • [1] Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity
    Arican, O
    Aral, M
    Sasmaz, S
    Ciragil, P
    [J]. MEDIATORS OF INFLAMMATION, 2005, (05) : 273 - 279
  • [2] The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
    Austin, LM
    Ozawa, M
    Kikuchi, T
    Walters, IB
    Krueger, JG
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) : 752 - 759
  • [3] IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes
    Boniface, K
    Bernard, FX
    Garcia, M
    Gurney, AL
    Lecron, JC
    Morel, F
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (06) : 3695 - 3702
  • [4] Braff MH, 2006, CURR TOP MICROBIOL, V306, P91
  • [5] Cutaneous defense mechanisms by antimicrobial peptides
    Braff, MH
    Bardan, A
    Nizet, V
    Gallo, RL
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (01) : 9 - 13
  • [6] Natural killer and natural killer-T cells in psoriasis
    Cameron, AL
    Kirby, B
    Fei, W
    Griffiths, CEM
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2002, 294 (08) : 363 - 369
  • [7] IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
    Chan, Jason R.
    Blumenschein, Wendy
    Murphy, Erin
    Diveu, Caroline
    Wiekowski, Maria
    Abbondanzo, Susan
    Lucian, Linda
    Geissler, Richard
    Brodie, Scott
    Kimball, Alexa B.
    Gorman, Daniel M.
    Smith, Kathleen
    Malefyt, Rene de Waal
    Kastelein, Robert A.
    McClanahan, Terrill K.
    Bowman, Edward P.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (12) : 2577 - 2587
  • [8] CD8+ T-CELLS IN PSORIATIC LESIONS PREFERENTIALLY USE T-CELL RECEPTOR V(BETA)3 AND/OR V(BETA)13.1 GENES
    CHANG, JCC
    SMITH, LR
    FRONING, KJ
    SCHWABE, BJ
    LAXER, JA
    CARALLI, LL
    KURLAND, HH
    KARASEK, MA
    WILKINSON, DI
    CARLO, DJ
    BROSTOFF, SW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) : 9282 - 9286
  • [9] Charles P, 1999, J IMMUNOL, V163, P1521
  • [10] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
    Chaudhari, U
    Romano, P
    Mulcahy, LD
    Dooley, LT
    Baker, DG
    Gottlieb, AB
    [J]. LANCET, 2001, 357 (9271) : 1842 - 1847